Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Head-To-Head Contrast: Tredegar (NYSE:TG) vs. Ivanhoe Mines (OTCMKTS:IVPAF)
TG Stock Tumbles 19% As It Incurs Q3 Loss on Soft Construction Demand
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
Tredegar Reports Third Quarter 2026 Results
Tredegar Plans to Release Third Quarter 2026 Financial Results on November 6, 2026
2 Stocks That May Benefit from Data Center Build-out
Tredegar Appoints Cindy Yao as Vice President, Chief Financial Officer and Treasurer
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Tredegar Announces Departure of Kevin Donnelly, Executive Vice President, General Counsel and Corporate Secretary
Tredegar Provides Update on One Tredegar Transformation
BlackRock Inc. Purchases New Position in Tredegar Corporation $TG
Connor Clark & Lunn Investment Management Ltd. Buys New Position in Tredegar Corporation $TG
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
Tredegar Announces Election of Ana Dutra to Board of Directors
Tredegar Q2 Earnings Rise Y/Y on Aluminum Extrusions Gains
Tredegar (NYSE:TG) Share Price Crosses Above 200 Day Moving Average – Here’s Why
Tredegar Reports Second Quarter 2026 Results
Tredegar Plans to Release Second Quarter 2026 Financial Results on August 7, 2026
Tredegar Announces the Retirement of Frasier W. Brickhouse II, Chief Financial Officer, Treasurer and Vice President, Effective September 1, 2026
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia